Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Pazopanib Versus Sunitinib in Patients With Renal Cell Carcinoma

BACKGROUND: In a phase 3, randomized, open-label trial (COMPARZ; NCT00720941), pazopanib was found to be non-inferior to sunitinib in terms of progression-free survival in patients with metastatic renal cell carcinoma with no prior therapy. Overall treatment differences were evaluated in a post hoc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Beaumont, Jennifer L., Salsman, John M., Diaz, Jose, Deen, Keith, McCann, Lauren, Powles, Thomas, Hackshaw, Michelle D., Motzer, Robert J., Cella, David
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4996632/
https://ncbi.nlm.nih.gov/pubmed/27000445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29888
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados